Eye disease management still suffers from important limitations:

For front of the eye diseases, progressive & irreversible vision losses are often caused by high rates of non-compliance to daily eyedrop treatments : 45% glaucoma patients¹ don’t respect their prescriptions (<80% of the dose)² leading to reduced efficacy.

Only 5% of the drug content in an eyedrop will be absorbed by the eye, meaning that 95% is wasted in tears and blinking.

Since poor yield eyedrops are not suitable to treat back of the eye diseases, retinal disorders require invasive intra-ocular injections. Performed at the hospital by an ophthalmologist, these injections generate stress & pain for the patients & high associated costs for the healthcare systems (treatment, hospital fees).

Most patients regularly forget about their eye drops, favoring their disease progression.

Prof. J.F. KOROBELNIK, M.D., Ph.D.

Bordeaux University Hospital

Too frequent injections cause patients to stop their treatment.

Eye disease patients’ representative association

Eye disease management still suffers from important limitations:

Only 5% of the drug content in an eyedrop will be absorbed by the eye, meaning that 95% is wasted in tears and blinking.

Most patients regularly forget about their eye drops, favoring their disease progression.

Prof. J.F. KOROBELNIK, M.D., Ph.D.

Bordeaux University Hospital

Too frequent injections cause patients to stop their treatment.

Eye disease patients’ representative association

Eye disease management still suffers from important limitations:

Only 5% of the drug content in an eyedrop will be absorbed by the eye, meaning that 95% is wasted in tears and blinking.

Most patients regularly forget about their eye drops, favoring their disease progression.

Prof. J.F. KOROBELNIK, M.D., Ph.D.

Bordeaux University Hospital

Too frequent injections cause patients to stop their treatment.

Eye disease patients’ representative association

BIOPHTA’s mini-tablet (3mm diameter) is applied by the patient directly on the eye surface: this ophthalmic insert is made of patented biopolymers that jellify when placed on the eye, thus developing a strong adhesion by creating disulfide bonds with the ocular surface.

When applied, our ophthalmic insert transforms into a hydrogel pellet that stays in place on the eye and releases a continuous and controlled low dose of the drug.

BIOPHTA’s Drug Delivery pharmaceutical platform is protected by strong intellectual property (3 patent families).

This technology offers four unique dedicated features:

Initially in dry & solid form to facilitate its self-application by the patients, our treatment instantly transforms into a hydrogel when it comes into contact with the tearfilm of the eye and avoids causing any foreign body sensation.

Creating covalent bonds with the natural mucins of the eye surface allows our hydrogel to perfectly stay in place for 7 days.

Biopolymer matrix composed of a tight nanofiber network enables the slow release of the drug content in a fine and continuous microdosing.

Topical treatment of the retina, thanks to an increase of the ocular drug absorption by the specific properties of these novel biopolymers.

Creating covalent bonds with the natural mucins of the eye surface allows our hydrogel to perfectly stay in place for 7 days.

Biopolymer matrix composed of a tight nanofiber network enables the slow release of the drug content in a fine and continuous microdosing.

Topical treatment of the retina, thanks to an increase of the ocular drug absorption by the specific properties of these novel biopolymers.

BIOPHTA’s Ophthalmic Insert overcomes efficacy issues of eyedrops and high costs of ocular injections. It is a global solution with technological features tailored for the treatment of both front and back of the eye diseases. It is the first time a therapy displays such innovative properties to disrupt both front of the eye & retina treatment.

Pipeline

Our non-invasive Drug Delivery Ocular Inserts have the ability to be used with multiple therapeutic compounds to target several indications.

We plan ultimately to use our versatile Drug Delivery technological platform with the goal of addressing retinal diseases like diabetic macular edema ($4.3 billion global market value) in replacement of current intra-ocular injections.

Hence, our roadmap is primarily driven by the rapid initiation of a First in Human pilot study that can be enabled in 2023 thanks to a formulation of our sustained release insert in the treatment of glaucoma. Approximately 76 million people worldwide are affected by glaucoma which accounts for a $6.9 billion global prescription eyedrops market. This First in Human pilot study using our ophthalmic insert platform technology will then allow us to develop other formulations for initiating additional programs in parallel.